VIK Group of Companies Plans to Increase Veterinary Drug Exports by 45% by 2030

The company also plans to increase the number of partner countries from 51 to 100, including BRICS member states. As part of its development, VIC has outlined four strategic directions, including the launch of a new production facility for the manufacture of coccidiostatics and vaccines under the Immunovax brand. In addition, the focus will be on import substitution of veterinary drugs for small pets.

The growth of the veterinary drug market in RUSSIA is also noticeable: according to data for 2023, its volume increased by 40% compared to the previous year, reaching 97.7 billion rubles with VAT, with a forecast of doubling to 178.6 billion rubles by 2030. Representatives of diplomatic missions from 14 countries, including Bangladesh, Brazil, India and others, took part in the event dedicated to these issues.